Literature DB >> 19579018

The cytotoxic activity of the phage E protein suppress the growth of murine B16 melanomas in vitro and in vivo.

Raúl Ortiz1, Jose Prados, Consolacion Melguizo, Ana R Rama, Ana Segura, Fernando Rodríguez-Serrano, Houria Boulaiz, Fidel Hita, Antonio Martinez-Amat, Roberto Madeddu, Juan L Ramos, Antonia Aranega.   

Abstract

Novel treatment modalities, including gene therapy, are needed for patients with advanced melanoma. The E gene from the phage varphiX174 encodes a 91-aa protein which lyses Escherichia coli by formation of a transmembrane tunnel structure. To evaluate whether this E gene has a cytotoxic impact on melanoma cells in vitro and in vivo, and could therefore be used as a new therapeutic strategy for this tumor type, we selected the B16-F10 murine melanoma cell line as a model. We used a nonviral gene delivery approach (pcDNA3.1/E plasmid) to study the inhibition of melanoma cells' proliferation in vitro and direct intratumoral injection of pcDNA3.1/E complexed with jetPEI to deliver E cDNA to rapidly growing murine melanomas, and found that the E gene has both a strong antiproliferative effect in B16-F10 cells in vitro and induces an efficient decrease in melanoma tumor volume in vivo (90% in 15 days). Interestingly, the GFP-E fusion protein expressed in melanoma cells was located in the mitochondria. In vitro and in vivo analysis demonstrated significant functional and morphological mitochondrial alterations accompanied by a significant increase of cytochrome c and active caspase-3 and -9 in transfected cells, which suggests that tumoral cell death is mediated by the mitochondrial apoptotic pathway. These results show that E gene expression in melanoma cells has an extraordinary antitumor effect, which means it may be a new candidate for an effective strategy for melanoma treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19579018     DOI: 10.1007/s00109-009-0493-9

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  35 in total

1.  Genetic evidence that the bacteriophage phi X174 lysis protein inhibits cell wall synthesis.

Authors:  T G Bernhardt; W D Roof; R Young
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

2.  The cytotoxic activity of the bacteriophage lambda-holin protein reduces tumour growth rates in mammary cancer cell xenograft models.

Authors:  Chukwuma A Agu; Reinhard Klein; Sonja Schwab; Marielle König-Schuster; Petra Kodajova; Michael Ausserlechner; Bernhard Binishofer; Udo Bläsi; Brian Salmons; Walter H Günzburg; Christine Hohenadl
Journal:  J Gene Med       Date:  2006-02       Impact factor: 4.565

3.  Saporin as a novel suicide gene in anticancer gene therapy.

Authors:  N Zarovni; R Vago; T Soldà; L Monaco; M S Fabbrini
Journal:  Cancer Gene Ther       Date:  2006-09-29       Impact factor: 5.987

4.  Tumour malignancy loss and cell differentiation are associated with induction of gef gene in human melanoma cells.

Authors:  H Boulaiz; J Prados; C Melguizo; J A Marchal; E Carrillo; M Peran; F Rodríguez-Serrano; A Martínez-Amat; O Caba; F Hita; A Concha; A Aránega
Journal:  Br J Dermatol       Date:  2008-06-28       Impact factor: 9.302

5.  Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches.

Authors:  Eva Maria Brandtner; Petra Kodajova; Juraj Hlavaty; Gerrit Jandl; Walter Tabotta; Brian Salmons; Walter H Günzburg; Christine Hohenadl
Journal:  J Gene Med       Date:  2008-02       Impact factor: 4.565

Review 6.  Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma.

Authors:  Jürgen Eberle; Lothar F Fecker; Amir M Hossini; Bahtier M Kurbanov; Henry Fechner
Journal:  Exp Dermatol       Date:  2008-01       Impact factor: 3.960

Review 7.  Emerging therapies for melanoma.

Authors:  Rajini Katipamula; Svetomir N Markovic
Journal:  Expert Rev Anticancer Ther       Date:  2008-04       Impact factor: 4.512

8.  Genetic construction, expression, and characterization of a single chain anti-CEA antibody fused to cytosine deaminase from yeast.

Authors:  Silvia Zamboni; Alessandra Mallano; Michela Flego; Alessandro Ascione; Maria Luisa Dupuis; Mara Gellini; Stefano Barca; Maurizio Cianfriglia
Journal:  Int J Oncol       Date:  2008-06       Impact factor: 5.650

Review 9.  Prodrug cancer gene therapy.

Authors:  Cestmir Altaner
Journal:  Cancer Lett       Date:  2008-05-27       Impact factor: 8.679

10.  A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus.

Authors:  Ju-mei Zhao; Yan-jun Wen; Qiu Li; Yong-sheng Wang; Hong-bo Wu; Jian-rong Xu; Xian-cheng Chen; Yang Wu; Ling-yu Fan; Han-shuo Yang; Tao Liu; Zhen-yu Ding; Xiao-bo Du; Peng Diao; Jiong Li; Hong-bing Wu; Bing Kan; Song Lei; Hong-xin Deng; Yong-qiu Mao; Xia Zhao; Yu-quan Wei
Journal:  FASEB J       Date:  2008-08-20       Impact factor: 5.191

View more
  3 in total

1.  5-Fluorouracil-loaded poly(ε-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer.

Authors:  Raúl Ortiz; José Prados; Consolación Melguizo; José L Arias; M Adolfina Ruiz; Pablo J Alvarez; Octavio Caba; Raquel Luque; Ana Segura; Antonia Aránega
Journal:  Int J Nanomedicine       Date:  2012-01-09

2.  Specific Colon Cancer Cell Cytotoxicity Induced by Bacteriophage E Gene Expression under Transcriptional Control of Carcinoembryonic Antigen Promoter.

Authors:  Ana R Rama; Rosa Hernandez; Gloria Perazzoli; Miguel Burgos; Consolación Melguizo; Celia Vélez; Jose Prados
Journal:  Int J Mol Sci       Date:  2015-06-04       Impact factor: 5.923

3.  Antitumor Effect of the Ethanolic Extract from Seeds of Euphorbia lathyris in Colorectal Cancer.

Authors:  Cristina Mesas; Rosario Martínez; Raúl Ortíz; Milagros Galisteo; María López-Jurado; Laura Cabeza; Gloria Perazzoli; Consolación Melguizo; Jesús M Porres; Jose Prados
Journal:  Nutrients       Date:  2021-02-09       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.